Press coverage about Align Technology (NASDAQ:ALGN) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Align Technology earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.3894310258529 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Align Technology (NASDAQ:ALGN) opened at 188.13 on Tuesday. Align Technology has a 12 month low of $83.27 and a 12 month high of $191.78. The company has a market capitalization of $15.08 billion, a price-to-earnings ratio of 64.43 and a beta of 1.54. The firm’s 50-day moving average is $181.76 and its 200 day moving average is $153.16.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.12. The firm had revenue of $356.50 million during the quarter, compared to the consensus estimate of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The company’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. Equities analysts expect that Align Technology will post $3.41 EPS for the current year.

A number of equities analysts have recently commented on ALGN shares. Piper Jaffray Companies restated a “buy” rating and issued a $176.00 price objective on shares of Align Technology in a research report on Friday, July 28th. Morgan Stanley reiterated an “overweight” rating and set a $175.00 target price on shares of Align Technology in a research report on Monday, June 19th. They noted that the move was a valuation call. Northcoast Research reiterated a “buy” rating and set a $186.00 target price (up from $164.00) on shares of Align Technology in a research report on Wednesday, June 21st. Stifel Nicolaus reiterated a “buy” rating and set a $200.00 target price (up from $145.00) on shares of Align Technology in a research report on Friday, June 23rd. Finally, Leerink Swann reiterated an “outperform” rating and set a $199.00 target price (up from $194.00) on shares of Align Technology in a research report on Friday, July 28th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $188.80.

WARNING: “Align Technology (ALGN) Getting Somewhat Positive Media Coverage, Accern Reports” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/10/align-technology-algn-getting-somewhat-positive-media-coverage-accern-reports.html.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Insider Buying and Selling by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Stock Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related stocks with our FREE daily email newsletter.